Jordan JFDA Market Surveillance and Inspection of Medical Devices

1. Key takeaways

JFDA market surveillance is a four-dimensional network: random sampling and testing of devices on the market in the quality control laboratories, inspection of distribution channels to verify compliance with storage and handling requirements, review of the ongoing compliance of labelling and advertising, and monitoring of adverse events and safety signals through the national vigilance system. The GRZAN conclusion is that Jordanian market regulation covers four lines — product, channel, labelling and signals — and a company cannot escape it by excelling on only one of them, because a weakness on any single line is enough to draw regulatory attention.

The second takeaway: inspections cover institutions, points of sale and clinics. The JFDA’s monitoring and inspection campaigns at premises where devices and consumables circulate, at points of sale and at clinics are carried out on a continuing basis, so exposure to inspection is not limited to importation but extends to where the product is actually sold and used. For importers and distributors alike, this means that every link in the chain can expect a visit, not only the first one.

The third takeaway: the 2017 Law on the Control and Inspection of Economic Activities provides the procedural foundation for on-site inspections and penalties, and in 2025 Jordan went further and updated its market control requirements, raising the baseline for what inspectors expect to find.

2. Legal basis

Clause numbers are subject to the Arabic originals published in the Jordanian Official Gazette and by the JFDA. The table shows how the procedural law, the circulation criteria and the 2025 update stack together: one governs how inspection is conducted, one defines the conditions being inspected, and the most recent one raises the requirements themselves.

3. Expert insights

Insight one: random sampling and testing is the core instrument on the product line. The JFDA performs random sampling and testing of devices on the market in its quality control laboratories. If the test results for a sampled product fail to meet the standards, this directly triggers delisting, recall or administrative penalties. Because the sampling is random, no batch on the market can be assumed to be outside the authority’s reach.

Insight two: distribution channel inspections verify “condition compliance”. The inspection items target whether storage and handling conditions match what the dossier declares and what good storage practice requires. Missing temperature records and failure to segregate nonconforming products are among the most frequent findings in on-site inspections, which means the gap is usually between what was promised on paper and what is done in the warehouse.

Insight three: review of labelling and advertising is a continuing obligation. The JFDA reviews the compliance of labelling and advertising on an ongoing basis. This means that a label which was compliant at registration may become non-compliant when regulations change or product information changes, and companies must maintain it continuously rather than treating the approval as a one-time clearance.

Insight four: laser devices and filler injection products are controlled more strictly. The JFDA has adopted strict control measures: import invoices for all types of laser devices may only be finalised after the Directorate of Licensing for Professions and Establishments of the Ministry of Health has issued a no-objection position, and importers of sterilisers, detergents and filler injection products must retain, for each batch, the import invoice and a sales list stating to whom the products were sold. These categories therefore carry record-keeping duties that go beyond the ordinary device rules.

Insight five: the 2025 update of market control requirements will raise inspection intensity. In 2025 Jordan updated the market control requirements for medical products, sterilisers, detergents and cosmetics. Combined with the monitoring and inspection campaigns the JFDA continues to run, companies should prepare on the assumption that inspection frequency will rise.

4. Practical recommendations

First, self-assess against the four-dimensional network. Build separate self-inspection checklists for each line: product (testing), channel (storage and handling), labelling (labels and advertising) and signals (vigilance). Only by scoring each line separately can a company see which one is its weakest point.

Second, keep labelling continuously compliant. When regulations change or product information changes, update the label promptly and supplement the JFDA file, so that what is on the market always matches what is on record.

Third, establish dedicated compliance processes for special categories. Laser devices and filler injection products each carry additional controls, so separate processes should be set up for them rather than folding them into the general device workflow.

Fourth, agree on inspection cooperation duties with the AR. When an on-site inspection occurs, the speed of the AR’s response directly affects the outcome, so this should be specified in the agreement.

5. Verification checklist

• □ Self-inspection checklists are built along the four lines: product, channel, labelling and signals
• □ The ongoing compliance of labelling and advertising is confirmed (including updates after regulatory changes)
• □ Dedicated compliance processes exist for laser and filler injection products
• □ The AR’s cooperation duties and deadlines during JFDA inspections are specified in the agreement
• □ Storage and handling conditions across the distribution chain are checked against the dossier declarations
• □ Inspection priorities following the 2025 market control requirements update are tracked
• □ Cited clause numbers are verified against the Arabic originals of the Official Gazette

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages adverse event reporting and recall coordination with the JFDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com